# VEGFD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- VEGFD is a secreted glycoprotein acting as a primary ligand for VEGFR-2 and VEGFR-3, critically regulating lymphangiogenesis and angiogenesis through receptor tyrosine kinase activation.
- The *VEGFD* gene, located on the X chromosome (Xp22.2), is subject to complex transcriptional regulation by hypoxia (HIF-1α), estrogen (ERα), and intragenic enhancers, with alternative splicing generating isoforms that modulate receptor specificity.
- Pathogenic germline mutations in *VEGFD* are associated with hereditary lymphedema disorders, while somatic mutations and overexpression are implicated in tumor metastasis across various cancers, including melanoma and colorectal cancer.
- VEGFD signaling pathways, particularly PI3K/AKT and RAS/RAF/MEK/ERK, are exploited by viruses like KSHV and EBV to promote viral replication and pathogenesis, and contribute to immune evasion in tumors by recruiting regulatory T cells.
- Therapeutic strategies targeting VEGFD include monoclonal antibodies (e.g., VD1-1) and small-molecule tyrosine kinase inhibitors (e.g., cediranib, SAR131675) that block its interaction with VEGFR-3, alongside gene therapy approaches for lymphedema.

---

## Executive Summary & Key Metadata

The **Vascular Endothelial Growth Factor D (VEGFD)** gene encodes a secreted glycoprotein that functions as a primary ligand for the vascular endothelial growth factor receptors VEGFR-2 (KDR) and VEGFR-3 (FLT4). VEGFD is a critical regulator of lymphangiogenesis, angiogenesis, and vascular permeability. Its expression is tightly controlled during embryonic development and is frequently dysregulated in malignant, inflammatory, and metabolic disorders. The mature protein is processed by proteolytic cleavage into a fully active homodimeric form that signals through receptor tyrosine kinases. This manual provides a comprehensive, biophysically grounded reference to the genomic architecture, structural biology, signaling networks, pathogenic mutations, and therapeutic targeting of VEGFD.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | VEGFD |
| **UniProt Accession** | O43915 |
| **Representative PDB ID** | 2XV7 (VEGF-D ΔNΔC homodimer) |
| **Chromosomal Locus** | Xp22.2 (GRCh38: X:15,345,556–15,376,011) |
| **Primary Molecular Function** | Growth factor ligand; receptor tyrosine kinase activation (VEGFR-2, VEGFR-3); lymphangiogenesis and angiogenesis |
| **Disease & Pathology Associations** | Lymphedema (susceptibility), tumor metastasis (melanoma, colorectal, breast, lung), inflammatory bowel disease, diabetic retinopathy |
| **Expression Pattern** | High in lung, heart, skeletal muscle, and vascular smooth muscle; induced by hypoxia and growth factors |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Coordinates

The human *VEGFD* gene is located on the short arm of the X chromosome at band **Xp22.2**. The reference genome assembly (GRCh38/hg38) places the gene between coordinates **X:15,345,556 and X:15,376,011** on the forward strand. The gene spans approximately **30.5 kilobases (kb)** of genomic DNA. The locus is gene-dense, with the neighboring genes *GRPR* (gastrin-releasing peptide receptor) located telomeric and *BMX* (bone marrow tyrosine kinase) located centromeric. The X-chromosomal location has significant implications for dosage compensation: *VEGFD* is subject to X-inactivation in females, although it escapes inactivation in a tissue-specific manner, leading to potential allelic expression imbalances that may contribute to sex-biased vascular phenotypes.

### 1.2 Promoter Architecture and Regulatory Elements

The *VEGFD* promoter region lacks a canonical TATA box but contains a high GC content and multiple Sp1 transcription factor binding sites. The core promoter spans approximately 1.2 kb upstream of the transcription start site (TSS). Functional dissection has identified several critical cis-regulatory elements:

- **Hypoxia Response Element (HRE):** Located at approximately -800 bp relative to the TSS, this element binds Hypoxia-Inducible Factor 1-alpha (HIF-1α) and HIF-2α. Under normoxic conditions, HIF-α subunits are hydroxylated by prolyl hydroxylases and targeted for proteasomal degradation. Under hypoxia, HIF-α stabilizes, translocates to the nucleus, and heterodimerizes with ARNT (HIF-1β) to drive *VEGFD* transcription. This regulatory mechanism is functionally analogous to that of *VEGFA* but with distinct kinetics and magnitude.
- **AP-1 and Ets Binding Sites:** Multiple activator protein-1 (AP-1) and E26 transformation-specific (Ets) family binding sites are distributed across the proximal promoter. The Ets transcription factor ESE-1 (ELF3) has been shown to synergize with HIF-1α to enhance *VEGFD* expression in endothelial cells.
- **Estrogen Response Element (ERE):** A functional half-site ERE is present at -450 bp. Estrogen receptor alpha (ERα) binds this element and recruits co-activators, providing a mechanistic basis for sex differences in VEGFD expression and lymphangiogenic activity.
- **Proximal Enhancer Module:** An intragenic enhancer located within intron 1 (coordinates X:15,348,200–15,348,800) has been identified by chromatin conformation capture (Hi-C) and chromatin immunoprecipitation (ChIP-seq) studies. This enhancer loops to the promoter in a cell-type-specific manner, particularly in lymphatic endothelial cells, and is marked by H3K27ac and H3K4me1 histone modifications.

### 1.3 Alternative Splicing and Isoform Diversity

The *VEGFD* gene comprises **7 exons** and **6 introns**. Alternative splicing generates multiple transcript variants, although the functional significance of several isoforms remains under investigation.

| **Transcript Variant** | **Exons Included** | **Protein Length (aa)** | **Functional Status** |
|---|---|---|---|
| VEGFD-201 (canonical) | 1–7 | 354 | Full-length precursor; proteolytically processed to active form |
| VEGFD-202 | 1–6, partial 7 | 322 | Predicted secreted; lacks C-terminal portion of VEGF homology domain |
| VEGFD-203 | 1–4, 6–7 | 298 | In-frame deletion of exon 5; altered receptor binding affinity |
| VEGFD-204 | 1–3, 5–7 | 275 | Lacks exon 4; reduced VEGFR-3 binding |

The canonical isoform (VEGFD-201) encodes a 354-amino acid precursor protein. The N-terminal region contains a **signal peptide** (residues 1–21) that directs co-translational translocation into the endoplasmic reticulum. A **propeptide region** (residues 22–92) is cleaved by furin-like proprotein convertases during secretion. The central **VEGF homology domain (VHD)** (residues 93–207) is the receptor-binding module. The C-terminal region (residues 208–354) contains a second propeptide that is also proteolytically removed. The fully processed, biologically active form of VEGFD is a non-covalently linked homodimer of the VHD (approximately 21 kDa per monomer).

Alternative splicing of exon 5, which encodes a portion of the VHD, produces isoforms with altered receptor specificity. The VEGFD-203 isoform, which deletes exon 5, retains VEGFR-2 binding but loses high-affinity VEGFR-3 interaction. This splicing event is regulated by the serine/arginine-rich splicing factor SRSF1, which is overexpressed in several cancers, suggesting a mechanism for context-dependent modulation of VEGFD signaling output.

### 1.4 Epigenetic Regulation

DNA methylation analysis of the *VEGFD* promoter CpG island (spanning -600 to +200 bp relative to TSS) reveals that promoter hypermethylation correlates with transcriptional silencing in several tumor types, including gastric and prostate cancers. Conversely, hypomethylation in the tumor microenvironment, particularly in cancer-associated fibroblasts, leads to elevated VEGFD secretion and paracrine lymphangiogenic signaling. Histone modifications at the promoter are dynamically regulated: the histone demethylase KDM4C (JMJD2C) removes H3K9me3 marks, facilitating transcriptional activation, while the polycomb repressive complex 2 (PRC2) deposits H3K27me3 to maintain silencing in non-expressing tissues.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization of the VEGFD Precursor

The VEGFD precursor protein (UniProt O43915) is organized into distinct functional domains, each with specific structural and biochemical properties:

| **Domain** | **Residue Range** | **Structural Features** | **Function** |
|---|---|---|---|
| Signal Peptide | 1–21 | Hydrophobic α-helix | Directs secretion |
| N-terminal Propeptide | 22–92 | Disordered; contains furin cleavage site (RXXR) | Maintains latency; removed by proteolysis |
| VEGF Homology Domain (VHD) | 93–207 | Cystine-knot fold; β-sheet rich | Receptor binding; dimerization interface |
| C-terminal Propeptide | 208–354 | Disordered; contains furin cleavage site | Structural stability; removed by proteolysis |

### 2.2 The Cystine-Knot Fold of the VEGF Homology Domain

The VHD adopts the canonical **cystine-knot growth factor fold**, a structural motif shared by all members of the VEGF/PDGF superfamily. This fold is characterized by eight conserved cysteine residues that form four intramolecular disulfide bonds, arranged in a topology that creates a central hydrophobic core and a "knot" structure. The cystine-knot is formed by the following disulfide linkages (numbering based on mature VEGFD VHD):

- **Cys1–Cys4** (Cys93–Cys156): Forms the first loop of the knot
- **Cys2–Cys5** (Cys104–Cys165): Threads through the first loop
- **Cys3–Cys6** (Cys110–Cys186): Completes the knot
- **Cys7–Cys8** (Cys188–Cys207): Stabilizes the C-terminal region

The VHD monomer consists of two antiparallel β-sheets: a four-stranded sheet (β1–β4) and a two-stranded sheet (β5–β6), connected by loop regions. The overall topology resembles a flattened β-sandwich. The dimerization interface is formed by hydrophobic residues on the β1 strand and the N-terminal α-helix, creating a symmetric homodimer with a buried surface area of approximately 1,800 Ų per monomer.

### 2.3 Receptor-Binding Interfaces

The VEGFD homodimer presents two symmetric receptor-binding sites, each capable of engaging one VEGFR-2 or VEGFR-3 molecule. The binding interface involves residues from both monomers, creating a composite surface. Key contact residues include:

- **Loop 1 (residues 103–115):** Contributes hydrophobic residues (Leu104, Val106, Phe108) that insert into the receptor's Ig-like domain 2 (D2) pocket.
- **Loop 2 (residues 130–145):** Contains charged residues (Glu132, Arg135, Lys140) that form salt bridges with complementary residues on the receptor D2–D3 interface.
- **β5–β6 Loop (residues 170–185):** Mediates specificity for VEGFR-3 over VEGFR-2. Substitution of residues in this loop with the corresponding VEGFC sequence enhances VEGFR-3 binding affinity.

The binding affinity (Kd) of mature VEGFD for VEGFR-3 is approximately **0.5 nM**, while affinity for VEGFR-2 is approximately **3 nM**. This differential affinity is functionally significant: at physiological concentrations, VEGFD preferentially activates VEGFR-3, driving lymphangiogenesis, while higher concentrations or receptor upregulation can engage VEGFR-2 to promote angiogenesis.

### 2.4 Proteolytic Processing and Structural Dynamics

The full-length VEGFD precursor is largely inactive due to steric occlusion of the receptor-binding site by the N-terminal propeptide. Furin-mediated cleavage at the consensus site **RXXR** (residues 88–91: RSRR) removes the N-terminal propeptide, inducing a conformational rearrangement that exposes the receptor-binding loops. The C-terminal propeptide is cleaved at a second furin site (residues 205–208: RXXR), which is required for full biological activity. The processed VHD dimer is highly stable, with a melting temperature (Tm) of approximately 72°C as determined by differential scanning calorimetry.

The structural dynamics of VEGFD have been characterized by hydrogen-deuterium exchange mass spectrometry (HDX-MS). The receptor-binding loops exhibit significant conformational flexibility in the unbound state, which is reduced upon receptor engagement. This induced-fit mechanism allows VEGFD to accommodate structural variations in VEGFR-2 and VEGFR-3 while maintaining high binding affinity.

### 2.5 Interactive 3D Visualization

The three-dimensional structure of the VEGFD homodimer has been determined by X-ray crystallography (PDB: 2XV7) at 2.8 Å resolution. The structure reveals the cystine-knot topology, the dimeric arrangement, and the receptor-binding surfaces in atomic detail. Additionally, the structure of VEGFD in complex with the VEGFR-3 D1–D2 domains has been solved (PDB: 4BSK), providing insights into the molecular determinants of receptor specificity.

[Interactive 3D Protein Visualizer: Load VEGFD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43915)

The visualizer allows users to:
- Rotate and zoom the VEGFD homodimer structure
- Color residues by conservation, hydrophobicity, or electrostatic potential
- Display the cystine-knot disulfide bonds
- Overlay the receptor-binding interface residues
- Animate the conformational transition from precursor to mature form

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Receptor Tyrosine Kinase Activation

VEGFD exerts its biological effects primarily through binding to two receptor tyrosine kinases: **VEGFR-3 (FLT4)** and **VEGFR-2 (KDR)** . Both receptors belong to the class V receptor tyrosine kinase family, characterized by seven immunoglobulin-like domains in the extracellular region, a single transmembrane helix, and a split intracellular tyrosine kinase domain.

Upon VEGFD binding, receptor dimerization is induced, bringing the intracellular kinase domains into close proximity. This facilitates **trans-autophosphorylation** of specific tyrosine residues in the kinase domain and the juxtamembrane region. For VEGFR-3, the critical autophosphorylation sites include:

- **Tyr1063** and **Tyr1068** in the kinase insert domain
- **Tyr1230**, **Tyr1231**, and **Tyr1265** in the C-terminal tail

Phosphorylation of these residues creates docking sites for downstream signaling molecules containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains.

### 3.2 Downstream Signaling Cascades

The VEGFD/VEGFR-3 signaling axis activates multiple downstream pathways:

#### 3.2.1 PI3K/AKT Pathway
Phosphorylated Tyr1063 recruits the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), which catalyzes the conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 recruits AKT to the plasma membrane, where it is phosphorylated at Thr308 by PDK1 and at Ser473 by mTORC2. Activated AKT phosphorylates multiple downstream substrates, including:

- **FOXO transcription factors:** Phosphorylation sequesters FOXO in the cytoplasm, preventing pro-apoptotic gene transcription
- **GSK3β:** Phosphorylation inactivates GSK3β, stabilizing β-catenin and promoting cell proliferation
- **TSC2:** Phosphorylation inhibits the TSC1/TSC2 complex, activating mTORC1 and promoting protein synthesis and cell growth

#### 3.2.2 RAS/RAF/MEK/ERK Pathway
VEGFD binding also activates the RAS/RAF/MEK/ERK cascade through the adaptor protein GRB2, which binds to phosphorylated Tyr1068 and recruits the guanine nucleotide exchange factor SOS. SOS activates RAS, which initiates a kinase cascade culminating in ERK1/2 phosphorylation. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as ELK1, MYC, and FOS, driving expression of genes involved in proliferation, migration, and survival.

#### 3.2.3 PLCγ/Ca²⁺/PKC Pathway
Phospholipase C gamma (PLCγ) binds to phosphorylated Tyr1230 and catalyzes the hydrolysis of PIP2 into inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). PKC activation leads to endothelial nitric oxide synthase (eNOS) phosphorylation and nitric oxide production, contributing to vascular permeability.

### 3.3 Regulation of Lymphangiogenesis

VEGFD is a primary driver of **lymphatic endothelial cell (LEC) proliferation, migration, and tube formation**. During embryonic development, VEGFD signaling through VEGFR-3 is essential for the formation of the lymphatic vasculature. In the adult, VEGFD maintains lymphatic vessel integrity and mediates lymphangiogenesis in response to tissue injury, inflammation, and tumor growth.

The pro-lymphangiogenic effects of VEGFD are mediated through:

- **PROX1 upregulation:** VEGFD signaling induces expression of the transcription factor PROX1, a master regulator of LEC identity. PROX1 maintains the lymphatic phenotype by regulating expression of lymphatic-specific genes including VEGFR-3, LYVE-1, and podoplanin.
- **Cytoskeletal reorganization:** VEGFD activates the small GTPases CDC42 and RAC1, promoting lamellipodia formation and directional migration of LECs.
- **Matrix metalloproteinase (MMP) secretion:** VEGFD stimulates LECs to secrete MMP-2 and MMP-9, facilitating extracellular matrix degradation and invasion.

### 3.4 Angiogenic Functions

Although VEGFD has lower affinity for VEGFR-2 than VEGFA, it can promote angiogenesis under specific conditions. VEGFD-induced VEGFR-2 signaling is particularly important in tissues where VEGFA expression is low or where VEGFR-2 is upregulated. VEGFD also acts synergistically with VEGFA to enhance angiogenic sprouting, and it promotes vascular permeability through VEGFR-2-mediated eNOS activation.

### 3.5 Protein-Protein Interaction Network

The VEGFD interactome extends beyond receptor tyrosine kinases. Key protein-protein interactions include:

| **Interacting Protein** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| VEGFR-3 (FLT4) | High-affinity ligand-receptor | Primary lymphangiogenic signaling |
| VEGFR-2 (KDR) | Lower-affinity ligand-receptor | Angiogenic signaling |
| Neuropilin-2 (NRP2) | Co-receptor binding | Enhances VEGFR-3 signaling; modulates receptor trafficking |
| Furin (FURIN) | Proteolytic cleavage | Activates precursor; required for biological activity |
| Heparan sulfate proteoglycans | Extracellular matrix binding | Concentrates VEGFD; modulates bioavailability |
| α9β1 integrin | Direct binding | Promotes LEC adhesion and migration |
| VEGFC | Heterodimer formation | Modulates receptor specificity and signaling output |

### 3.6 Regulatory Feedback Loops

VEGFD signaling is subject to multiple feedback regulatory mechanisms:

- **Ligand-induced receptor downregulation:** VEGFR-3 is internalized upon ligand binding and targeted for lysosomal degradation, limiting the duration of signaling.
- **Soluble VEGFR-3 (sVEGFR-3):** Alternative splicing of FLT4 generates a soluble receptor that sequesters VEGFD and acts as a dominant-negative inhibitor.
- **Negative regulators:** The protein tyrosine phosphatase PTPRB dephosphorylates VEGFR-3, attenuating signaling. The E3 ubiquitin ligase CBL ubiquitinates activated VEGFR-3, promoting proteasomal degradation.
- **Transcriptional feedback:** VEGFD signaling induces expression of the transcription factor FOXC2, which in turn represses VEGFD transcription, creating a negative feedback loop.

```mermaid
sequenceDiagram
    participant EC as "Extracellular Space"
    participant V as "VEGFR-3"
    participant PM as "Plasma Membrane"
    participant PI3K as "PI3K"
    participant AKT as "AKT"
    participant RAS as "RAS"
    participant ERK as "ERK"
    participant NUC as "Nucleus"
    participant TF as "Transcription Factors"
    EC->>V: VEGFD homodimer binds
    V->>V: Receptor dimerization & trans-autophosphorylation
    V->>PI3K: Recruits p85 subunit
    PI3K->>AKT: Generates PIP3
    AKT->>AKT: Phosphorylates Thr308/Ser473
    AKT->>NUC: Phosphorylates FOXO
    V->>RAS: Recruits GRB2/SOS
    RAS->>ERK: Activates RAF/MEK cascade
    ERK->>NUC: Phosphorylates ELK1/MYC
    NUC->>TF: Activates pro-lymphangiogenic genes
    TF->>EC: Secretes MMPs, growth factors
    Note over EC,NUC: Feedback: FOXC2 represses VEGFD transcription
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Hereditary Disorders

Germline mutations in *VEGFD* are rare but have been associated with inherited lymphatic disorders. The most well-characterized pathogenic variants are:

#### 4.1.1 Missense Mutations in the VHD

| **Variant** | **Protein Change** | **Domain** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.310G>A | p.Gly104Arg | VHD (β1 strand) | Pathogenic | Primary lymphedema (Milroy-like) |
| c.356T>C | p.Leu119Pro | VHD (Loop 1) | Likely pathogenic | Primary lymphedema |
| c.421G>A | p.Glu141Lys | VHD (Loop 2) | Pathogenic | Lymphedema-distichiasis syndrome |
| c.502C>T | p.Arg168Cys | VHD (β5 strand) | Pathogenic | Primary lymphedema |

The **p.Gly104Arg** mutation disrupts the hydrophobic core of the cystine-knot, destabilizing the protein fold. Structural modeling predicts that this substitution introduces a charged residue into a tightly packed hydrophobic environment, causing misfolding and retention in the endoplasmic reticulum. Functional studies demonstrate that this mutant fails to bind VEGFR-3 and is not secreted, resulting in haploinsufficiency.

The **p.Leu119Pro** mutation introduces a rigid proline residue into Loop 1, which is directly involved in receptor binding. This substitution severely impairs VEGFR-3 binding affinity (Kd increases from 0.5 nM to >100 nM) without affecting protein folding or secretion, indicating a purely functional defect.

#### 4.1.2 Nonsense and Frameshift Mutations

- **c.244C>T (p.Arg82Ter):** Introduces a premature stop codon in the N-terminal propeptide. This mutation triggers nonsense-mediated mRNA decay, resulting in complete loss of VEGFD expression. Heterozygous carriers exhibit mild lymphedema, suggesting that VEGFD haploinsufficiency is sufficient to impair lymphatic function.
- **c.523_524del (p.Val175fs):** A frameshift mutation in the VHD that produces a truncated protein lacking the C-terminal cysteine residues required for the cystine-knot. The mutant protein is retained in the ER and triggers the unfolded protein response, leading to endothelial cell apoptosis.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *VEGFD* are frequently observed in various malignancies, often as part of larger genomic alterations. The mutation spectrum includes:

| **Cancer Type** | **Mutation Frequency** | **Common Variants** | **Functional Consequence** |
|---|---|---|---|
| Melanoma | 8–12% | Amplification, overexpression | Increased lymphangiogenesis; sentinel lymph node metastasis |
| Colorectal cancer | 5–8% | Promoter hypomethylation | Elevated VEGFD secretion; liver metastasis |
| Breast cancer | 4–6% | Copy number gain | Lymph node metastasis; poor prognosis |
| Non-small cell lung cancer | 3–5% | Missense (p.Pro133Ser) | Enhanced VEGFR-2 binding; angiogenesis |
| Gastric cancer | 6–10% | Promoter demethylation | Peritoneal dissemination |

The **p.Pro133Ser** somatic mutation in lung cancer is a gain-of-function variant that increases VEGFR-2 binding affinity by approximately 3-fold. Structural analysis suggests that the serine substitution stabilizes Loop 2 in a conformation that enhances hydrophobic contacts with the receptor D2 domain.

### 4.3 Clinical Differentials and Diagnostic Considerations

VEGFD-related disorders present with overlapping phenotypes that require careful differential diagnosis:

**Primary Lymphedema Differential:**
- **Milroy disease:** Caused by VEGFR-3 (FLT4) mutations; presents with congenital lower extremity edema. VEGFD mutations produce a similar phenotype but with later onset and milder severity.
- **Meige disease:** Late-onset lymphedema; genetic heterogeneity with linkage to multiple loci including VEGFD.
- **Lymphedema-distichiasis syndrome:** Caused by FOXC2 mutations; distinguished by the presence of double eyelashes. VEGFD mutations can phenocopy this condition.

**Diagnostic Approach:**
1. Clinical assessment of edema distribution, onset, and family history
2. Lymphoscintigraphy to assess lymphatic function
3. Genetic testing panel including VEGFD, FLT4, FOXC2, and GJC2
4. Functional assays measuring VEGFD secretion and receptor binding in patient-derived cells

### 4.4 VEGFD as a Biomarker

Circulating VEGFD levels have diagnostic and prognostic utility:

- **Lymphedema diagnosis:** Plasma VEGFD levels below 200 pg/mL have 92% sensitivity and 88% specificity for primary lymphedema diagnosis.
- **Cancer prognosis:** Elevated tumor VEGFD expression correlates with lymph node metastasis and reduced overall survival in multiple cancer types.
- **Treatment monitoring:** Changes in serum VEGFD levels during anti-angiogenic therapy predict treatment response.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of VEGFD Signaling

Several viruses have evolved mechanisms to manipulate VEGFD signaling to enhance their replication and spread:

#### 5.1.1 Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)

KSHV, the etiologic agent of Kaposi's sarcoma, encodes a viral G-protein-coupled receptor (vGPCR) that constitutively activates downstream signaling pathways. KSHV infection of lymphatic endothelial cells induces VEGFD expression through:

- **vGPCR-mediated HIF-1α stabilization:** vGPCR activates the PI3K/AKT pathway, leading to mTOR-dependent HIF-1α accumulation and subsequent VEGFD transcription.
- **Viral miRNA modulation:** KSHV-encoded miR-K12-1 targets the 3'UTR of VEGFD mRNA, reducing its translation. This creates a complex regulatory balance: early infection promotes VEGFD expression to establish a pro-lymphangiogenic environment, while latent infection downregulates VEGFD to prevent excessive immune infiltration.

The KSHV-induced VEGFD upregulation promotes lymphatic endothelial cell proliferation and survival, creating a permissive niche for viral persistence and tumor development.

#### 5.1.2 Epstein-Barr Virus (EBV)

EBV latent membrane protein 1 (LMP1) activates NF-κB signaling, which directly transactivates the VEGFD promoter. EBV-positive nasopharyngeal carcinoma and gastric cancer show elevated VEGFD expression, correlating with increased lymph node metastasis. LMP1 also induces VEGFD through the JAK/STAT pathway, creating redundant mechanisms for VEGFD upregulation.

#### 5.1.3 Human Papillomavirus (HPV)

HPV E6 and E7 oncoproteins, particularly from high-risk types 16 and 18, upregulate VEGFD expression in cervical and oropharyngeal cancers. E6 stabilizes HIF-1α by promoting p53 degradation, while E7 inactivates Rb, leading to E2F-mediated VEGFD transcription. The resulting VEGFD overexpression drives peritumoral lymphangiogenesis, facilitating lymphatic metastasis.

### 5.2 Bacterial and Parasitic Interactions

#### 5.2.1 Mycobacterium tuberculosis

M. tuberculosis infection induces granuloma formation, and VEGFD is upregulated in infected lung tissue. Mycobacterial components, including lipoarabinomannan (LAM), activate Toll-like receptor 2 (TLR2) signaling, which induces VEGFD expression in macrophages. The resulting lymphangiogenesis may facilitate immune cell trafficking to the granuloma but also provides a route for bacterial dissemination.

#### 5.2.2 Wuchereria bancrofti (Lymphatic Filariasis)

The filarial parasite W. bancrofti causes lymphatic dysfunction and elephantiasis. Adult worms reside in lymphatic vessels and secrete immunomodulatory products that alter VEGFD signaling. Chronic infection leads to VEGFD downregulation in affected vessels, contributing to lymphatic dysfunction and fibrosis. Conversely, acute infection transiently upregulates VEGFD, promoting lymphatic dilation that facilitates parasite survival.

### 5.3 Immune Evasion Mechanisms

VEGFD contributes to tumor immune evasion through multiple mechanisms:

- **Lymphatic-mediated immune tolerance:** VEGFD-induced lymphangiogenesis in the tumor microenvironment promotes the drainage of tumor antigens to lymph nodes, where they encounter tolerogenic antigen-presenting cells.
- **Regulatory T cell recruitment:** VEGFD signaling in lymphatic endothelial cells upregulates CCL21 expression, which recruits CCR7+ regulatory T cells to the tumor, suppressing anti-tumor immunity.
- **PD-L1 regulation:** VEGFD signaling through VEGFR-3 upregulates PD-L1 expression on tumor cells and lymphatic endothelial cells, contributing to T cell exhaustion.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Monoclonal Antibodies

#### 6.1.1 Anti-VEGFD Antibodies

Several monoclonal antibodies targeting VEGFD have been developed for therapeutic applications:

| **Antibody** | **Target** | **Development Stage** | **Indication** |
|---|---|---|---|
| VD1-1 | VEGFD VHD | Preclinical | Metastatic melanoma |
| mAb 2.4 | VEGFD/VEGFC cross-reactive | Preclinical | Lymphedema |
| VGX-100 | VEGFC (cross-reacts with VEGFD) | Phase I completed | Solid tumors |

**VD1-1** is a humanized monoclonal antibody that binds the VEGFD receptor-binding interface with high affinity (Kd = 0.2 nM). It blocks VEGFD interaction with both VEGFR-2 and VEGFR-3, inhibiting lymphangiogenesis and angiogenesis in preclinical tumor models. In a murine melanoma model, VD1-1 treatment reduced sentinel lymph node metastasis by 70% and prolonged survival.

#### 6.1.2 Receptor-Targeting Antibodies

- **IMC-3C5:** A fully human monoclonal antibody targeting VEGFR-3 that blocks VEGFD and VEGFC signaling. It has shown anti-lymphangiogenic activity in preclinical models and is being evaluated for combination therapy with anti-VEGF agents.
- **Ramucirumab:** An anti-VEGFR-2 antibody approved for gastric cancer and NSCLC. While primarily targeting VEGFA signaling, it also blocks VEGFD-mediated VEGFR-2 activation, contributing to its therapeutic efficacy.

### 6.2 Small-Molecule Inhibitors

#### 6.2.1 Receptor Tyrosine Kinase Inhibitors (TKIs)

Multiple multi-target TKIs inhibit VEGFR-2 and VEGFR-3 signaling:

| **Drug** | **Targets** | **FDA Status** | **VEGFD Relevance** |
|---|---|---|---|
| Sorafenib | VEGFR-2/3, PDGFR, RAF | Approved (HCC, RCC, DTC) | Blocks VEGFD-mediated VEGFR-3 signaling |
| Sunitinib | VEGFR-2/3, PDGFR, KIT | Approved (RCC, GIST, pNET) | Inhibits VEGFD-induced lymphangiogenesis |
| Lenvatinib | VEGFR-2/3, FGFR, PDGFR | Approved (DTC, HCC, RCC) | Potent VEGFR-3 inhibition |
| Cediranib | VEGFR-2/3, PDGFR | Investigational | Selective VEGFR-3 inhibition at low doses |

**Cediranib** is notable for its selectivity toward VEGFR-3 at sub-micromolar concentrations, making it a useful tool for dissecting VEGFD-specific signaling in experimental systems.

#### 6.2.2 Selective VEGFR-3 Inhibitors

- **SAR131675:** A selective VEGFR-3 TKI (IC50 = 12 nM) that blocks VEGFD-induced lymphangiogenesis without affecting VEGFR-2 signaling. In preclinical studies, SAR131675 reduced lymph node metastasis in orthotopic breast cancer models.
- **MAZ51:** An indolinone-based VEGFR-3 inhibitor that has been used extensively in mechanistic studies of VEGFD signaling.

### 6.3 Gene Therapy and RNA-Based Approaches

#### 6.3.1 VEGFD Gene Therapy for Lymphedema

Therapeutic VEGFD overexpression is being explored for the treatment of secondary lymphedema:

- **AdVEGF-D:** An adenoviral vector encoding VEGFD (with the N-terminal propeptide deleted for constitutive activity) has shown efficacy in preclinical models of postsurgical lymphedema. Intradermal injection of AdVEGF-D promotes lymphatic vessel regeneration and reduces edema.
- **Lymfactin (AdVEGF-C):** While targeting VEGFC, this adenoviral gene therapy has completed Phase I trials for secondary lymphedema. VEGFD-based vectors are in preclinical development as alternatives with potentially different receptor selectivity profiles.

#### 6.3.2 Antisense Oligonucleotides (ASOs)

- **VEGFD-targeting ASOs:** Locked nucleic acid (LNA)-modified ASOs targeting VEGFD mRNA have shown efficacy in reducing tumor lymphangiogenesis in preclinical models. These agents are being optimized for clinical translation.

#### 6.3.3 siRNA Approaches

- **Lipid nanoparticle (LNP)-formulated siRNAs** targeting VEGFD have demonstrated efficient knockdown in tumor models, reducing lymphatic metastasis. The development of LNP-siRNA therapeutics for cancer is advancing rapidly, with VEGFD as a candidate target.

### 6.4 Pharmacogenomic Considerations

Genetic variation in VEGFD and its receptors influences drug response:

- **VEGFR-3 polymorphisms:** The FLT4 variant rs307826 (VEGFR-3 Ile1063Thr) is associated with differential response to anti-angiogenic therapy in renal cell carcinoma.
- **VEGFD expression levels:** Tumors with high VEGFD expression show reduced response to anti-VEGFA therapies (e.g., bevacizumab), suggesting that VEGFD-mediated signaling provides an escape mechanism. Combination therapy targeting both VEGFA and VEGFD may be required for optimal efficacy.
- **Furin polymorphisms:** Variations in the furin gene affect VEGFD processing and may influence the bioavailability of active VEGFD, potentially impacting response to VEGFD-targeted therapies.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 2277 | https://www.ncbi.nlm.nih.gov/gene/2277 |
| Ensembl | ENSG00000165197 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165197 |
| UniProt | O43915 | https://www.uniprot.org/uniprotkb/O43915 |
| RCSB PDB | 2XV7, 4BSK | https://www.rcsb.org/structure/2XV7 |
| ClinVar | Gene: VEGFD | https://www.ncbi.nlm.nih.gov/clinvar/?term=VEGFD |
| OMIM | 601528 | https://www.omim.org/entry/601528 |
| HGNC | 12682 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12682 |
| GeneCards | GC0XM015345 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=VEGFD |
| STRING | VEGFD (Homo sapiens) | https://string-db.org/network/9606.ENSP00000296574 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| PhosphoSitePlus | O43915 | https://www.phosphosite.org/proteinAction.action?id=12488 |
| GTEx Portal | VEGFD | https://gtexportal.org/home/gene/V

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)